Sanofi taps Oncodesign's macrocycles for kinase targets
This article was originally published in Scrip
Sanofi is to tap fellow French firm Oncodesign for its macrocyclic small molecule kinase inhibitor discovery expertise. Oncodesign stands to receive up to €130 million in technology access fee and discovery, development, regulatory and commercial milestones as well as low-single digit royalties under the four-year agreement. The extent to which the deal is back-loaded is not clear.